1. Introduction {#s0005}
===============

Alzheimer\'s disease (AD) is a primary and progressive neurodegenerative disorder that results in cognitive impairment, memory deficits and increasing functional losses in patients ([@bb0030], [@bb0205]). AD is the most common cause of dementia, accounting for 50% to 60% of cases ([@bb0030]). The worldwide prevalence of dementia due to AD is estimated to be around 1% for individuals between 60 and 64 years of age ([@bb0200]). In the occidental world, dementia prevalence increases exponentially with age, varying from 24 to 33% after the age of 84 years ([@bb0200]). The number of people aged over 60 years and suffering from dementia worldwide was estimated at 46,8 million in 2015 and this number is expected to double at every 20 years ([@bb0200]). Although these statistics have increased the public awareness and improved the quality of health services, population aging tends to increase considerably the disease incidence. Economic and social burden turn AD into a grave public health issue, with urgent necessity for effective methods to understand its pathophysiology, thereby allowing the development of better treatments ([@bb0075]).

The exact pathophysiology of AD is not well understood, although the amyloid cascade theory has been largely accepted. This theory proposes the precipitation of beta-amyloid proteins and formation of extracellular plaques, consequently leading to inflammatory processes and ultimately to cognitive deficits ([@bb0075], [@bb0245], [@bb0175]). Other anatomo-pathological alteration of AD is the presence of neurofibrillary tangles, mainly composed of hyperfosforilated tau protein ([@bb0030], [@bb0045], [@bb0075]). Association of these components starts a cascade of events, contributing to excitotoxicity, neuroinflammation and dysfunction of protein degradation mechanisms ([@bb0045], [@bb0160]). The order by which these events occur is yet not fully understood, and controversial evidences regarding the relationships between their causes and effects can be found in literature ([@bb0010], [@bb0030]). The progressive accumulation of abnormal proteins has led to the extensive investigation of imaging markers that could identify early accumulation of protein metabolites. In this context, developing biomarkers is an active research area with progress in the neuroimaging field and radiopharmaceutical analysis of β-amyloid (Aβ) or tau protein in cerebrospinal fluid (CSF). However, there is no current gold-standard for the clinical practice yet, and this fact highlights a lack of validation and standardization by wider studies ([@bb0015], [@bb0030]). These tests would be important for detecting AD at early stages, anticipating diagnosis and treatment as well as monitoring therapeutic responses.

Some anatomical changes detected by magnetic resonance imaging (MRI) are considered fair indicators for initial changes at individual levels ([@bb0150], [@bb0160]). Several studies based on MRI have shown that volumetric reductions of hippocampus, entorhinal cortex, posterior cingulate gyrus, amygdala and parahippocampal gyrus are indicators of early AD ([@bb0020], [@bb0040], [@bb0070], [@bb0090], [@bb0100], [@bb0195], [@bb0215], [@bb0225], [@bb0240], [@bb0255], [@bb0260]). The measurement of cortical thickness by MRI also may reveal reduction of these and other regions, such as medial temporal, parietal and frontal lobes ([@bb0025], [@bb0095], [@bb0170], [@bb0185]). Therefore, MRI shows initial reduction at the parahippocampal gyrus, followed by a widespread pattern of volume reduction involving the temporal medial lobe and posterior parietal region ([@bb0055], [@bb0155], [@bb0165], [@bb0235]). Large numbers of cross-sectional and a small number of longitudinal studies ([@bb0135]) have shown increased rate of atrophy (3.5% annually) of the hippocampus in patients with AD, relative to controls (1.7% annually) ([@bb0005]). In another study, the atrophy rate for the entorhinal cortex (7.1 ± 3.2%/year) was higher than that of the hippocampus (5.9 ± 2.4%/year) ([@bb0105]). In later AD stages, atrophy progresses to the prefrontal cortex ([@bb0210]). In general, structural MRI exams are considered biomarkers of AD progression according to the International Working Group ([@bb0110]). MRI based volume measurements are correlated with Braak stage and neuronal counts ([@bb0035], [@bb0140]).

Most studies on the evolution of brain atrophy in AD have focused on the earlier disease stages, i.e. the transition from health to the first phase of AD ([@bb0180]). Neuroimaging studies of AD patients in later stages (CDR 3), to the best of our knowledge, have not been reported yet and could reveal details on the disease progression regarding neuronal degeneration and the follow-up of therapeutic approaches. Only theoretical models have been proposed to describe the full trajectories of different biomarkers for AD ([@bb0150], [@bb0145]). This research evaluated the brain morphometry variations in AD patients from CDR 1 to CDR 3. The structural profile associated with AD severity up to later disease stages was also identified.

2. Material and methods {#s0010}
=======================

2.1. Subjects {#s0015}
-------------

Subjects gave written informed consent, and this study was approved by the Ethics Committee of the Clinics Hospital - Ribeirão Preto Medical School (HCRP 9613-15). In case of participants with impaired autonomy and judgment due to AD, the consent form was read and signed by their carers. Controls and patients aged 60 years or older and from both genders, were included prospectively during 2015--2016 (n = 44). AD patients were followed by the Geriatrics Service of the Ribeirao Preto Medical School. The control group was composed of cognitively normal individuals paired by age (n = 16). Participants of this group were recruited from the university community, like, for instance, participants of physical activities for the third age. Inclusion criteria for the control group were having no memory complaints, no functional impairments and MMSE score above 25 for participants with at least four years of formal education and above 27 for participants with 8 years of formal education or over ([@bb0050]).

The diagnosis of probable Alzheimer\'s disease was made using Diagnostic and Statistical Manual for Mental Disorders V. The risk of circularity was avoided considering the natural history of the patient and the independent MRI exam evaluation of by two different physicians. Subjects who presented Fazekas scale ([@bb0115]) above 2 in a FLAIR MRI, even though they did not present clinical vascular dementia, were not included in the study. The following tests were applied for the exclusion of secondary causes of dementia: serology for HIV and syphilis, liver function, serum levels of Vitamin B12, Folic acid, calcium, TSH, complete blood count, renal function, electrolytes and fasting glycemia. Cognitive function was evaluated by the application of the Mini Mental State Exam (MMSE) ([@bb0130]) and Clinical Dementia Rating (CDR). Using the sum of boxes of CDR test, patients were classified into low (CDR1), moderate (CDR2) and high AD severity (CDR3) ([@bb0190]).

2.2. Image acquisition and processing {#s0020}
-------------------------------------

Images from all participants were acquired on a 3 T MRI (Philips Achieva) equipment. An 8-channel head coil was used to perform T1-weighted gradient echo sequences. Patients exhibiting severe AD were sedated by intravenous propofol drip infusion (4--7 mg/kg/h) for image acquisition. The following parameters were used in the acquisition of T1-weighted sequence: TR = 7 ms, TE = 3.2 ms, flip angle = 8°, FOV = 240 × 240 mm^2^, in-plane resolution = 0.9 × 0.9 mm^2^, slices = 170, and slice thickness = 1 mm. The time for structural image acquisition was 4 min and 27 s. No contrast agent was used in any subject.

After detailed visual inspection for the detection of motion artifacts or morphologic brain alterations that would exclude the participant from the study, volume and cortical thickness were measured automatically by the application of the Freesurfer version 5.3.0 image analysis suite, which is freely available for downloading (<http://surfer.nmr.mgh.harvard.edu>/). Images were batch processed, thus lessening repetitive work and decreasing error probability, once image processing was performed independently from the operator. Image processing included skull stripping, intensity normalization, tissue classification (parcellation), and cortical thickness and volume determinations. The intermediate step in this analysis, the automatic parcellation, relies on an intrinsic coordinate system, which stores a-priori statistics and class-conditional densities related to each location over the cortical surface. A reference set of 3D meshes, representing the manual parcellation made by specialists, allows incorporating an anatomical convention in the parcellation, especially in brain regions whose geometry is not predictive for parcel\'s tag. Thus, new individual brains are "warped" into the standard space and new subject\'s brain inherits the tags of the previously established model ([@bb0125]).

Quality of segmentation and parcellation of individual brain volumes were checked independently by two specialized radiologists. No parcellation needed to be excluded or manually repaired. Quantitative volume and cortical thickness data were obtained for regions defined by two atlases comprising two brain subdivision types: the Desikan brain atlas ([@bb0080]) for large areas such major brain lobes ([Fig. 3](#f0015){ref-type="fig"}) and the Destrieux brain atlas ([@bb0085]), which further divides the lobes into sulci and gyri regions ([Fig. 4](#f0020){ref-type="fig"}).

2.3. Statistical analysis {#s0025}
-------------------------

Volume of each brain region was normalized considering the total intra cranial volume so that inter-individual variations in head size were minimized ([@bb0250]). The estimated intra cranial volumes (eTIV) were automatically calculated by Freesurfer recon-all script, considering the volume-scaling factor derived by registration of each individual to the atlas template. Results regarding total intracranial volumes are presented in [Table 1](#t0005){ref-type="table"}. One-way ANOVA was used to test for differences between groups with respect to age, years of education, disease duration and MMSE score (p \< 0.05). Mean volume and cortical thickness with respective standard deviation were calculated for each group and brain region, and tested by one-way ANOVA (p \< 0.05, uncorrected). Both simple and multiple linear regression models were used to verify the presence of correlation of independent variables like age, years of formal education, sex and MMSE with the dependent variable normalized volume or cortical thickness. Differences between groups were visualized by overlaying color scales on 3D brain mesh representations.Table 1Demographic features of control and patient groups.Table 1Feature/groupControlsPatients CDR1Patients CDR2Patients CDR3Sample size16161513Age, mean ± std. (years)78 ± 480 ± 482 ± 482 ± 5Min. age (years)71717575Max. age (years)85879089Women (%)63446785MMSE score, mean ± std. (points)27 ± 222 ± 213 ± 40Disease duration, mean ± std. (years)02 ± 17 ± 312 ± 1Education, mean ± std. (years)7 ± 4[a](#tf0005){ref-type="table-fn"}6 ± 55 ± 53 ± 3[a](#tf0005){ref-type="table-fn"}Intracranial volume (l)1.2 ± 0.21.3 ± 0.31.3 ± 0.21.3 ± 0.2[^1][^2]

3. Results {#s0030}
==========

[Table 1](#t0005){ref-type="table"} shows the demographic characteristics of the participants. Age was not significantly different between groups (p \> 0.05). There were differences between groups with respect to years of education only between controls and CDR3. The intracranial volumes of each group are listed in [Table 1](#t0005){ref-type="table"}.

Brain volume atrophy of patients suffering from AD at any stage was observed in the hippocampus, amygdala, entorhinal cortex, parahippocampal region, temporal pole and temporal lobe ([Fig. 1](#f0005){ref-type="fig"}). The absolute brain volumes for these cited regions are listed in [Table 2](#t0010){ref-type="table"}.Fig. 1Normalized brain volumes (mean ± standard deviation) expressed as a percentage of intracranial volume for controls (black), CDR1 (light blue), CDR2 (dark blue) and CDR3 (red) patient groups, whose brain regions showed significant volume change in all AD stages (\*p \< 0.05; \*\*p \< 0.01;\*\*\*p ≪ 0.001). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 1Table 2Absolute brain region volume (mm^3^) (mean ± standard deviation) values of each group whose brain regions showed linear volume reduction towards AD progression.Table 2Brain regionControlsCDR1CDR2CDR3Hippocampus3480(458)2953(556)2473(334)2034(605)Entorhinal1779(346)1383(444)1076(377)867(289)Amygdala1376(212)1204(260)1069(222)681(239)Parahippocampal gyrus3957(701)3314(912)2601(639)2200(677)Occipital temporal lateral1134(265)1003(261)896(220)687(310)

Significant differences between CDR1, CDR2 and CDR3, but with no differences between the CDR1 and the control groups are showed on [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}. The total brain volume was not significantly reduced over the AD progression, however white and gray matter volumes of CDR2 and CDR3 groups were markedly low ([Fig. 2](#f0010){ref-type="fig"}). Other brain regions presented significantly reduced volume only for patients in the CDR3 group (supplementary information - A). All brain regions showing significant differences between groups are represented in [Fig. 4](#f0020){ref-type="fig"}.Fig. 2Normalized brain volumes (mean ± standard deviation) expressed as a percentage of the intracranial volume for controls (black), CDR1 (light blue), CDR2 (dark blue) and CDR3 (red) patient groups, whose brain regions showed significant volume change in all AD stages, except CDR1 patients compared to the control group (\*p \< 0.05; \*\*p \< 0.01;\*\*\*p \< 0.001). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 2Fig. 3Continuing [Fig. 2](#f0010){ref-type="fig"}.Fig. 3Fig. 4Brain areas with significant atrophy over AD progression (A, B) segmentation by lobe atlas ([@bb0080]) and (C, D) sulci and gyri atlas ([@bb0085])). Colors represent regions with significant volumetric reduction (p \< 0.05) among groups (yellow), except for control and CDR1 (red), and control, CDR1 and CDR2 (orange) \[color should be used\]. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 4

High correlations were observed between normalized volume with multiples parameters as MMSE score, age, education level and gender for hippocampus, entorhinal, amygdala, inferior lateral ventricle, parahippocampal gyrus and lateral occipito-temporal sulcus ([Table 3](#t0015){ref-type="table"}). Age, education and gender variables showed high slope error, suggesting their fewer influence for these subjects.Table 3Multiple linear regression coefficients between brain region volumes and explanatory variables.Table 3RegionsInterceptMMSE slopeAge slopeEducation slopeGender slopeR^2^Hippocampus0.4196 ± 0.11560.0045 ± 0.0007− 0.0030 ± 0.0014− 0.0025 ± 0.0013− 0.0355 ± 0.01390.35Entorhinal0.0926 ± 0.05580.0023 ± 0.0004− 0.0003 ± 0.0006− 0.0007 ± 0.0006− 0.0119 ± 0.00670.32Amygdala0.1621 ± 0.05020.0022 ± 0.0003− 0.0013 ± 0.0006− 0.0009 ± 0.0006− 0.0099 ± 0.00600.41Inf. lat. ventricle− 0.2025 ± 0.1372− 0.0052 ± 0.00080.0049 ± 0.0017− 0.0001 ± 0.00020.0166 ± 0.01650.39Parahippocampal gyrus0.3627 ± 0.12630.0046 ± 0.0008− 0.0024 ± 0.0016− 0.0014 ± 0.0015− 0.0139 ± 0.01510.32Occipito-temporal sulcus0.0927 ± 0.04980.0015 ± 0.0003− 0.0004 ± 0.0006− 0.0007 ± 0.0005− 0.0079 ± 0.00590.19

Moderate linear correlation was observed between normalized volume and MMSE score for regions that decreased significantly in all stages of AD (R^2^ \< 0.36, [Fig. 5](#f0025){ref-type="fig"}). High linear correlation was observed between normalized volume and CDR values averaged by group for some regions ([Fig. 6](#f0030){ref-type="fig"}).Fig. 5Linear correlation between normalized volume and MMSE of each individual subject. Both sides included all groups indicated at the legend. Regression coefficients are inserted in the equation of each plot.Fig. 5Fig. 6Linear correlation between normalized volume and clinical dementia rate (CDR) values averaged by group. Regression coefficients are inserted in the equation of each plot.Fig. 6

[Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"} show the average cortical thickness values and standard deviations of each group. [Fig. 7](#f0035){ref-type="fig"} - left corresponds to brain regions that presented significant cortical thickness reduction for all AD stages. The same trend is true for the entorhinal cortices, with exception of the difference between CDR2 and CDR3 groups ([Fig. 7](#f0035){ref-type="fig"} - right). [Fig. 8](#f0040){ref-type="fig"} displays brain regions with significant differences between CDR1, CDR2 and CDR3, but with no differences between CDR1 and control groups.Fig. 7Cortical thickness values (mean ± standard deviation) for bilateral regions that showed significant reduction in all AD phases (left) and the same with exception between CDR2 and CDR3 (right) (\*\*p \< 0.01; \*\*\*p \< 0.001).Fig. 7Fig. 8Cortical thickness values (mean ± standard deviation) for bilateral regions that showed significant reduction in all AD phases, except between controls and CDR1 (\*\*p \< 0.01; \*\*\*p \< 0.001).Fig. 8

Other regions exhibiting significant cortical thickness reduction for specific groups have been included in supplementary information (B). [Fig. 9](#f0045){ref-type="fig"} presents graphically the regions exhibiting significant cortical thickness reduction over AD progression.Fig. 9Brain regions with cortical thickness reduction over the progression of AD. (A, B) Segmentation by considering Desikan template ([@bb0080])) and (C, D) sulci and gyri Destrieux template ([@bb0085])). Colors represent regions with significant volumetric reduction (p \< 0.01, uncorrected) among subject groups (yellow), except between control and CDR1 (red), and CDR1 and CDR2 (orange) \[color should be used\]. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 9

For the parahippocampal gyrus, multiple linear regression showed only MMSE as an explanatory variable correlated with cortical thickness (Y = 2.676 ± 0.774 + 0.027 ± 0.005 ∗ (MMSE) − 0.009 ± 0.009 ∗ (age) − 0.001 ± 0.009 ∗ (education) − 0.033 ± 0.093 ∗ (gender), R^2^ = 0.30). Moderate and high linear correlation was observed between cortical thickness of parahippocampal gyrus and MMSE (R^2^ = 0.32) and CDR (R^2^ = 0.997) average values by group, respectively ([Fig. 10](#f0050){ref-type="fig"}).Fig. 10Linear correlations between absolute cortical thickness and Mini Mental State Exam (MMSE) (left) and between average cortical thickness values average by group (with standard deviation) and clinical dementia rate (CDR). Regression coefficients are inserted in the equation of each plot.Fig. 10

4. Discussion {#s0035}
=============

Volumetric reduction of hippocampus, entorhinal cortex, posterior cingulate, amygdala and parahippocampal gyrus are indicators of early AD stages ([@bb0020], [@bb0040], [@bb0070], [@bb0090], [@bb0100], [@bb0195], [@bb0225], [@bb0240], [@bb0255], [@bb0260]). Studies have reported early hippocampal atrophy already in mild cognitive impairment (MCI), indicating that the atrophy rate in this region could identify patients suffering from MCI that would be further converted to AD ([@bb0215]). Other studies evaluated early and moderate AD patients and observed that the volumetric reduction is extended to frontal, parietal and temporal neocortex ([@bb0060]). These studies did not evaluate patients suffering from advanced AD stages. Such information could unveil details on the disease progression regarding neuronal degeneration and the follow-up of therapeutic approaches.

As previously reported ([@bb0020], [@bb0040], [@bb0070], [@bb0090], [@bb0100], [@bb0195], [@bb0225], [@bb0240], [@bb0255], [@bb0260]), brain regions affected by AD during its initial stages, such as hippocampus, amygdala, entorhinal, parahippocampal regions, temporal pole and temporal lobe, were found in this work to be significantly altered, by ANOVA test, even in individuals with severe AD (CDR 3) ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). These results indicate that rates of atrophy have not plateaued out at CDR 2--3, and in severe patients there is yet neuronal loss and gliosis. In addition, individuals, specifically, CDR 3, have multiple regions with lower volumes than individuals CDR 2 ([Fig. 4](#f0020){ref-type="fig"}). Moreover, normalized volume reduction was correlated mainly with AD progression ([Table 3](#t0015){ref-type="table"} and [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}). Other variables like age, education and gender showed high slope error ([Table 3](#t0015){ref-type="table"}), suggesting their lower influence for these subjects. These findings can add important information to the more accepted model in the literature that focused on early disease stages ([@bb0150]). The authors suggested that the atrophy quantified by MRI would be significantly larger at early AD stages and presented a plateau for severe patients. However, their patient group did not include those with extremely low MMSE values, which hindered inferences on the full AD trajectory.

Our results suggest that the volumetric atrophy ([Fig. 6](#f0030){ref-type="fig"}) begins at the parahippocampal gyrus (the entorhinal cortex), and has a widespread pattern of volume reduction involving the temporal medial lobe (hippocampus) and posterior parietal region (posterior cingulate) in agreement with literature ([@bb0055], [@bb0155], [@bb0165], [@bb0210], [@bb0235]). In the later AD stages, atrophy affects the prefrontal cortex in agreement with an experimental study with moderate AD patients ([@bb0210]). The hippocampus and parahippocampal regions showed high linear correlation between average volume and cortical thickness, and CDR rates (R^2^ \> 0.996) ([Fig. 6](#f0030){ref-type="fig"}, [Fig. 10](#f0050){ref-type="fig"}). The average volumetric reduction rate per CDR for hippocampus was 0.045%. The average thickness reduction rate for the parahippocampal gyrus was 0.30 mm per CDR. However, these results were gathered from an average of the group, and thus cannot be extrapolated for individual patients. Without a longitudinal study, it is impossible to know whether atrophy rates accelerate or decelerate in the later stages and we cannot explain why many people with AD do not survive for 12 years.

Analysis of variance indicated that only the thickness of parahippocampal gyrus significantly decreased in all AD progression ([Fig. 7](#f0035){ref-type="fig"}) stages, in accordance with previous reports ([@bb0025], [@bb0170]). Other regions, including the temporal, parietal and frontal lobes ([@bb0095]) showed cortical thickness reduction only at moderate and advanced stages of AD ([Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"}). One fact that may explain the discrepancies between our results and those reported in literature ([@bb0025], [@bb0065], [@bb0095], [@bb0170], [@bb0185]) are the number of images acquired and processing method used. [@bb0095] acquired multiple images (n = 4) of the same patient to improve the contrast--to-noise ratio and the quality of segmentation ([@bb0095]). For the segmentation of a single image, Blanck and collaborators corrected manually the segmentation of 25% of the subjects ([@bb0025]). The automatic segmentation is prone to error mainly at the borders of anatomical regions. Cortical thickness relies on border definition between gray and white matter and is even more dependent on the segmentation quality. In turn, segmentation quality depends on contrast--to-noise ratio, type of smoothing filter and segmentation parameters, with potential to add an error of 0.25 mm on cortical thickness values ([@bb0120]). Lastly, acquisition of several images and manual segmentation protocols are time-consuming procedures and may lead to human errors due to fatigue.

Even though AD mainly affects individuals above 65 years, we found considerable slope error for the age variable on multiple linear regression of volumetric atrophy ([Table 3](#t0015){ref-type="table"}). This strengthens the hypothesis that atrophy occurs by AD pathophysiological process and not only with advancing age. Also, the variable of years of education showed the same behavior ([Table 3](#t0015){ref-type="table"}). The education time of all subjects ranged predominantly between 0 and 6 years, different from the duration of formal education of European or North American samples. The consequences of a lower educational level in this study may have implications in the "cognitive reserve" usually regarded as an important trait that enables the individual to better tolerate cognitive abnormalities in late stages of the disease. Considering that MMSE was the main variable correlated on multiple linear regression with volumetric atrophy, we suggest that duration of formal education can be considered a proxy of cognitive reserve but not exclusively so. From this point of view, an alternative for years of formal education would be literacy, which would also provide some kind of cognitive reserve ([@bb0220]).

Our results advance one step further in relation to [@bb0045] results by pinpointing areas that were spared on the massive degeneration of the CDR 3 stage. Even though the CDR 3 group was not a large group (n = 13), we identified areas that do not change volume significantly even after a decade of disease onset. The analysis of both Desikan and Destrieux templates allowed us to observe details about spared areas like the frontomarginal gyrus, inferior occipital gyrus, subcentral gyrus, anterior cingulate gyrus, inferior frontal orbital gyrus, inferior triangular frontal gyrus, medial frontal gyrus, lingual gyrus, orbital gyrus, superior parietal gyrus, postcentral gyrus, rectus gyrus, subcallosal gyrus (see supplemental material). The preservation of these areas may represent a background for palliative care, improving wellbeing in later stages of life.

This study has some limitations. First, the number of subjects was relatively small given the difficulty to find healthy volunteers or patients suffering from "pure" AD. Several AD patients also presented concomitant microangiopathy, which led to their exclusion. Second, the proportions of males/females between groups were unavoidably unbalanced. Previous studies indicate that women may be at higher risk of developing severe disability than men in the advanced ages due to their longer survival ([@bb0230]). Third, education level of subjects was lower than subjects evaluated by other studies (i.e. [@bb0150]), and this may be an explanation for the difference at neuro-degeneration profile showed by [@bb0150], that needs to be evaluated on future studies. Other limitation for recruiting patients, especially for the severe AD group, was the necessity of sedation during image acquisition. Ideally, the study should have a longitudinal design in order to follow the same patient over each AD phase. However, this would be impractical due to the variability in disease duration and survival among the individual subjects.

5. Conclusion {#s0040}
=============

The most affected brain regions suffer atrophy without plateau phase until the later AD stages (CDR 2--3). These findings can add important information to the more accepted model in the literature that focuses mainly on early stages. Our findings permit a better understanding of the AD pathophysiology and the possible follow-up of drug effects that could modify the disease even during its late stages.
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Detailed cerebral volumetric and cortical thickness values found for control and experimental groups.Image 1
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[^1]: CDR: Clinical Dementia Rating. MMSE: Mini Mental State Exam.

[^2]: Significantly with p \< 0.05.
